

FOI REF: 26/072

**Eastbourne District General Hospital**

Kings Drive  
Eastbourne  
East Sussex  
BN21 2UD

4<sup>th</sup> February 2026

Tel: 0300 131 4500  
Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

### FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

- 1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to?**  
**111.**
- 2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:**

|   |           |
|---|-----------|
| • <b>BR (bendamustine + rituximab)</b>  | <b>0</b>  |
| • <b>Brukinsa (zanubrutinib)</b>  | <b>28</b> |
| • <b>Calquence (acalabrutinib)</b>  | <b>48</b> |
| • <b>Calquence (acalabrutinib) + Gazyva (obinutuzumab)</b>                          | <b>0</b>  |
| • <b>Calquence (acalabrutinib) + Venclyxto (venetoclax)</b>                         | <b>0</b>  |
| • <b>Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab)</b> | <b>0</b>  |
| • <b>FCR (fludarabine + cyclophosphamide + rituximab)</b>                           | <b>0</b>  |
| • <b>Fludarabine Monotherapy</b>  | <b>0</b>  |
| • <b>Gazyva (obinutuzumab) + chlorambucil</b>                                       | <b>0</b>  |
| • <b>Imbruvica (ibrutinib)</b>  | <b>21</b> |
| • <b>Venclyxto (venetoclax)</b>   | <b>10</b> |
| • <b>Venclyxto (venetoclax) + Gazyva (obinutuzumab)</b>                             | <b>0</b>  |
| • <b>Venclyxto (venetoclax) + rituximab</b>   | <b>2</b>  |
| • <b>Zydelig (idelalisib) + rituximab</b>   | <b>0</b>  |
| • <b>Imbruvica (ibrutinib) +Venclyxto (venetoclax)</b>                              | <b>3</b>  |
| • <b>Any other systemic anti-cancer therapy</b>                                     | <b>3</b>  |

Cont.../

3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:

|   |           |
|---|-----------|
| • <b>Brukinsa (zanubrutinib)</b>                | <b>21</b> |
| • <b>Calquence (acalabrutinib)</b>              | <b>33</b> |
| • <b>Imbruvica (ibrutinib)</b>                  | <b>2</b>  |
| • <b>Venclyxto (venetoclax)</b>                 | <b>3</b>  |
| • <b>Zydelig (idelalisib) + rituximab</b>       | <b>0</b>  |
| • <b>Any other systemic anti-cancer therapy</b> | <b>2</b>  |

4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.

**REALITY WW**

Prospective Cohort Study with Fixed-Duration Ibrutinib+ Venetoclax (I+V) First-Line Treatment in Patients with Chronic Lymphocytic Leukaemia in a Real-World Setting

0 Recruits

Closed to recruitment 25.11.2025

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department ([esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)